$282 Million is the total value of MPM BioImpact LLC's 12 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q4 2019 | ||||||||
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Repare Therapeutics, Inc. | 17 | Q2 2024 | 19.7% |
| iTeos Therapeutics, Inc. | 16 | Q2 2024 | 15.7% |
| Harpoon Therapeutics, Inc. | 15 | Q2 2023 | 27.6% |
| Cullinan Therapeutics, Inc. | 14 | Q2 2024 | 41.4% |
| TCR2 Therapeutics, Inc. | 14 | Q1 2023 | 18.0% |
| G1 Therapeutics, Inc. | 13 | Q4 2022 | 13.3% |
| Intellia Therapeutics, Inc. | 13 | Q2 2024 | 5.5% |
| Werewolf Therapeutics, Inc. | 13 | Q2 2024 | 6.8% |
| Y Mabs Therapeutics, Inc. | 12 | Q3 2022 | 5.4% |
| Crinetics Pharmaceuticals Inc. | 12 | Q2 2024 | 4.0% |
View MPM BioImpact LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-21 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| SC 13D/A | 2023-08-01 |
| SC 13D | 2023-06-12 |
| 4 | 2023-06-05 |
| 13F-HR | 2023-05-12 |
View MPM BioImpact LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.